Substituted pyrazoline compounds, their preparation and use...

Details Substituted pyrazoline compounds, their preparation and use... Substituted pyrazoline compounds, their preparation and use...

2011-03-01

2011-03-01

Loewe, Sun Jae Y (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S210180, C514S217090, C514S218000, C514S256000, C514S254050, C514S326000, C514S341000, C514S310000, C514S305000, C514S406000, C548S364100, C548S364400, C544S333000, C546S275100, C546S138000, C546S148000, C540S480000, C540S575000, C540S603000

Reexamination Certificate

active

07897589

ABSTRACT:
The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

REFERENCES:
patent: 5017596 (1991-05-01), Colombo et al.
patent: 5849931 (1998-12-01), Frigola-Constansa et al.
patent: 6118009 (2000-09-01), Torrens-Jover et al.
patent: 6187930 (2001-02-01), Torrens-Jover et al.
patent: 6410582 (2002-06-01), Merce-Vidal et al.
patent: 6509367 (2003-01-01), Martin et al.
patent: 6610737 (2003-08-01), Garzon et al.
patent: 6956033 (2005-10-01), Ogawa et al.
patent: 2002/0058816 (2002-05-01), Kordik et al.
patent: 2002/0156104 (2002-10-01), Adams et al.
patent: 2003/0022925 (2003-01-01), Merce-Vidal et al.
patent: 2003/0153569 (2003-08-01), Adams et al.
patent: 2004/0092535 (2004-05-01), Barsanti et al.
patent: 2005/0137251 (2005-06-01), Garzon et al.
patent: 2005/0171179 (2005-08-01), Lange et al.
patent: 2005/0222138 (2005-10-01), Ohhata et al.
patent: 2005/0282798 (2005-12-01), Lazzari et al.
patent: 2006/0020010 (2006-01-01), Altisen et al.
patent: 2006/0052315 (2006-03-01), Leung et al.
patent: 2006/0106014 (2006-05-01), Boddupalli et al.
patent: 2006/0128673 (2006-06-01), Firnges et al.
patent: 2006/0172019 (2006-08-01), Ralston et al.
patent: 2006/0189658 (2006-08-01), Altisen et al.
patent: 2006/0194843 (2006-08-01), Berdini et al.
patent: 2007/0073056 (2007-03-01), Torrens et al.
patent: 2009/0131497 (2009-05-01), Torrens Jover et al.
patent: 1 209 326 (1970-10-01), None
patent: 02 117 605 (1988-10-01), None
patent: WO 88/05046 (1988-07-01), None
patent: WO 88/06583 (1988-07-01), None
patent: WO 92/03421 (1992-03-01), None
patent: WO 00/76503 (2000-12-01), None
patent: WO 02/080909 (2002-10-01), None
patent: WO 2004/060882 (2004-07-01), None
patent: WO 2004/078261 (2004-09-01), None
patent: WO 2006/077414 (2006-07-01), None
patent: WO 2006/077419 (2006-07-01), None
patent: WO 2006/077425 (2006-07-01), None
patent: WO 2006/077428 (2006-07-01), None
http://mojo.calyx.net/˜olsen/MEDICAL/IOM/iom115054635.html (25 pages).
http://www.norml.org/index.cfm?Group—ID=7282&wtm—format=print (2 pages).
Muccioli et al., Expert Opinion Ther Patents (2006), 16 (10), 1405-1423).
http://www.nlm.nih.gov/medlineplus/ency/article/001553.htm (3 pages).
http://www.webmd.com/diet/tc/Obesity-Overview (3 pages).
http://health.yahoo.com/topic/addiction/abuse/article/pt/Psychology—Today—articles—pto—term—alcohol (6 pages).
Megard et al., “A co-culture based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation”, Brain Research, 927, 2002, 153-167.
Fact sheet Alzheimers association, 2 pages.
http://www.mayoclinic.com/health/alzheimers-disease/DS00161/DSECTION=3.
http://www.medindia.net/patients/patientinfo/Alzheimers—treatment.htm.
Zips et al, “new anticancer agents: in vitro and in vivo”, in vivo, 2005, 19, 1-7.
Torrens et al, caplus an 2007:82492.
Chawla et al., “Challenges in Polymorphism of Pharmaceuticals”, CRIPS vol. 5, No. 1, Jan.-Mar. 2004 (4 Pages.
Newman et al., “Solid-state analysis of the active pharmaceutical ingredient in drug products”, DDT vol. 8, No. 19, Oct. 2003, p. 898-905.
Chan et al., “N-substituted Pyrazoline-type Insecticides”, ACS Symposium Series, No. 800, p. 144-155 (2002); Chem. Abstr. XP002335857.
Meier et al., “Insecticidal Dihydropyrazoles with Reduced Lipophilicity”, ACS Symposium Series, No. 504 p. 313-326 (1992); Chem Abstr. XP002335858.
Meyer et al, “1,5-Diaryl-2,3-pyrrolidinediones—Phenylhydrazine Derivatives”, Journal of Organic Chemistry, vol. 22: 1565-1567 (1957); Chem Abstr. XP002335859.
International Search Report mailed Jul. 29, 2005 in International Application No. PCT/EP2005/001659.
Kenji Tamura et al., “One-Pot Synthesis of Trifluoroacetimidoyl Halides”, J. Org. Chem. 1993, 58, 32-38.
Hollister, L. E., “Health Aspects of Cannabis,” Pharmacological Reviews, vol. 38, No. 1, pp. 1-20 (1986).
Murphy, L. et al., Consroe and Sandyk, “Potential Role of Cannabinoids for Therapy of Neurological Disorders,” pp. 459-524, CRC Press (1992).
Slavinska, V. et al., “New Way for the Preparation of 4-Phenyl-2-Oxobutyric Acid Ethyl Ester,” Synthetic Communications, 26(11), 2229-2233 (1996).
Dujardin, G. et al., “A Straightforward Route to E-γ-Aryl-α-oxobutenoic Esters by One-step Acid-catalysed Crotonisation of Pyruvates,” Synlett, No. 1, pp. 147-149 (2001).
Pascual, Alfons, “Synthese des 5-[(Acetylhydrazono)-(4-chlorphenyl)-methyl]thiophen-2-yl-esters der Trifluormethansulfonsäure,” J. Prakt. Chem. 341, No. 7, pp. 695-700 (1999).
Lin, S. et al., “Regioselective Friedel-Crafts Acylation with Unsymmetrically Substituted Furandicarboxylic Acid Anhydride and Furan Acid Chloride: Syntheses of 4-Substituted 3-Arylcarbonyl-2-Phenylfuran and 3-Substituted 4-Arylcarbonyl-2-Phenylfuran,” Heterocycles, vol. 55, No. 2, pp. 265-277 (2001).
Rao, P. D. et al. “Rational Syntheses of Porphyrins Bearing up to Four Different Meso Substituents,” J. Org. Chem., 65, pp. 7323-7344 (2000).
Pearson, D.E. and Buehler, C.A., “Friedel-Crafts Acylation with little or No Catalyst,” Synthesis, No. 10: Oct., pp. 533-542 (1972).
Ross, Ruth A. et al., “Agonist-inverse agonist characterization at CB1and CB2cannabinoid receptors of L-759633, L759856 and AM830,” British Journal of Pharmacology 126, pp. 665-672 (1999).
Howlett, A.C. et al., “International Union of Pharmacology XXVII. Classification of Cannabinoid Receptors,” Pharmacological Reviews 54:161-202 (2002).
Compton, David R. et al., “In-Vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A): Inhibition of Δ9-Tetrahydrocannabinol-Induced Responses and Apparent Agonist Activity,” The Journal of Pharmacology and Experimental Therapeutics, vol. 277, No. 2, 277:588-594 (1996).
Woolfe G. et al., “The Evaluation of the Analgesic Action of Pethidine Hydrochloride (Demerol),” The Journal of Pharmacology and Experimental Therapeutics, vol. 80, pp. 300-307 (1944).
Desmedt L.K.C. et al. “Anticonvulsive Properties of Cinnarizine and Flunarizine in Rats and Mice,” Arzneim.-Forsch. (Drug Res.) 25, Nr. 9, pp. 1408-1413 (1975).
G. Colombo et al., “Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR 141716,” Life Sciences, vol. 63, No. 8 pp. PL 113-117 (1998).
Alpermann, H.G. et al., “Pharmacological Effects of Hoe 249: A New Potential Antidepressant,” Drug Development Research 25:267-282 (1992).
Seth, R. et al., “Chemistry and Pharmacology of Cannabis,” Progress in Drug Research, vol. 36:71-115 (1991).
Muccioli, G.G. et al., “CB1 and CB2 cannabinoid receptor antagonists and inverse agonists for obesity, metabolic syndrome and smoking cessation indications,” Expert Opinion on Therapeutic Patents, vol. 16, No. 10, pp. 1405-1423 (2006).
Lange, J.H.M. et al., “3,4-diarylpyrozolines as cannabinoid CB SUB 1 receptor antagonists with lower lipophilicity,” Bioorganic & Medicinal Chemistry Letters, vol. 15, No. 21, pp. 4794-4798 (2005).
Thomas, B.F. et al., “Long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide,” Bioorganic & Medicinal Chemistry, vol. 13, No. 18, pp. 5463-5474 (2005).

Affiliated with

Also associated with

Rating

Substituted pyrazoline compounds, their preparation and use... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted pyrazoline compounds, their preparation and use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrazoline compounds, their preparation and use... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2714577